Compare stocks

GRCE vs NRXS

Grace Therapeutics, Inc. Common Stock and Neuraxis, Inc.

Compare the businesses

Grace Therapeutics, Inc. Common Stock

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Open GRCE dashboard ↗

Neuraxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Open NRXS dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗